Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,723 recruiting studies in this area right now.
By phase
- Not applicable9,853
- Phase 24,482
- Phase 12,739
- Phase 1/Phase 21,693
- Phase 31,411
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,233
- Prostate Cancer660
- Cancer655
- Colorectal Cancer499
- Lung Cancer430
- Ovarian Cancer339
- Multiple Myeloma330
- Gastric Cancer301
- Pancreatic Cancer297
- Acute Myeloid Leukemia292
- Hepatocellular Carcinoma285
- Solid Tumor258
- Advanced Solid Tumor254
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer206
- Advanced Solid Tumors196
- Esophageal Cancer196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University316
- National Cancer Institute (NCI)291
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,429
- Texas642
- Arizona514
- Florida441
- Alabama419
- New York412
- Massachusetts341
- Maryland330
- New Jersey267
- Pennsylvania239
Recruiting studies20,723 total
- NCT06196255RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant or relapsed multiple myeloma
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Xuzhou, JiangsuAges 18–70 - NCT06196190Recruiting
Study on HPV after cone biopsy for cervical cancer
This study looks at women with early-stage cervical cancer (stage IB2) or a pre-cancer called AIS. The goal is to see if testing for HPV after a cone biopsy can help predict if the cancer will come back. Your HPV test results will be tracked over time.
HaifaAges 18–85 - NCT06196294RecruitingPhase 1
Engineered immune cells for cancers with GPC3 or mesothelin
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT06196788RecruitingPhase 2
Artery infusion chemo for advanced pancreatic cancer
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06197672RecruitingPhase 1
CAR T cells for CD4-positive AML before stem cell transplant
This trial tests a new type of immunotherapy (CAR T cells) designed to target and kill leukemia cells that have a specific marker (CD4). The goal is to help people with acute myeloid leukemia (AML) that has not responded to standard treatments get ready for a stem cell transplant.
Miami, FloridaAges 12 years+ - NCT06197581Recruiting
Safety of Radiation with Modern Breast Cancer Drugs
This study checks if giving certain modern breast cancer drugs at the same time as radiation is safe. It's for women who need radiation and are also taking one of these drugs: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy, or a HER2 inhibitor.
Beijing, Beijing MunicipalityAges 18–70 - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06198400Recruiting
Dye test for blood flow after pancreas surgery
This trial uses a special dye to check blood flow in the remaining part of your pancreas after surgery. It helps doctors see if the tissue is getting enough blood, which can improve healing and reduce complications.
Prague, Czech RepublicAges 18 years+ - NCT06199557RecruitingPhase 1/Phase 2
Gentle drug combo for AML or high-risk MDS
This trial tests a combination of two oral drugs (hydroxyurea and valproic acid, or 6-mercaptopurine and valproic acid) for people with AML or high-risk MDS who are too frail for standard chemotherapy. The goal is to see if this gentler treatment can help control the disease.
Bergen, BergenAges 18 years+ - NCT06200168RecruitingPhase 3
Electroacupuncture to prevent nausea during breast cancer chemo
This study tests whether electroacupuncture can help prevent nausea and vomiting caused by strong chemotherapy in people with breast cancer. If you're starting a certain type of chemo, this could help you feel better during treatment.
Xining, QinghaiAges 18–75 - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06200259Recruiting
Reducing Bowel Side Effects in Prostate Cancer Proton Therapy
This study tests a way to reduce stomach and bowel side effects of proton therapy for prostate cancer. It uses special software to place the proton beam more carefully, which may protect nearby organs.
Knoxville, TennesseeAges 18 years+ - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT06200974Recruiting
Genetic study of HDR brachytherapy for low-risk prostate cancer
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
Kelowna, British ColumbiaAges 18 years+ - NCT06200831Recruiting
Same surgery or two surgeries for colorectal cancer with liver spread
This trial compares having one surgery to remove both the colon tumor and liver tumors at the same time versus having two separate surgeries. It aims to find which approach is safer and works better for patients whose cancer has spread only to the liver.
OsloAges 18–80 - NCT06201247RecruitingEarly Phase 1
CD123-targeted immune cell therapy for relapsed/refractory AML
This early-phase trial tests an 'off-the-shelf' immune cell treatment (CAR-NK cells) that targets a protein called CD123 on leukemia cells. It's for people with AML that has returned or hasn't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06202118Recruiting
Alpha radiation therapy for breast cancer in older or frail patients
This trial tests a new type of radiation therapy (DaRT) that uses tiny, implantable seeds to deliver targeted alpha radiation to breast tumors. It is designed for older patients (65+) or those who are too frail for surgery, offering a less invasive option for controlling the cancer.
JerusalemAges 65–120 - NCT06201884RecruitingPhase 2
Walking program for older patients after cancer surgery
This study tests whether a special walking program (using a platform) can help older patients recover better after cancer surgery. If you are 65 or older and can walk on the platform for 10 minutes, you might be eligible.
CaenAges 65 years+ - NCT06202001RecruitingPhase 1/Phase 2
Three-drug combo for metastatic colorectal cancer as second treatment
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
BeijingAges 18–70
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,723 recruiting oncology studies from the U.S. registry right now, out of 32,139 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.